{"changes":[],"country":"US","description":"Anagram Therapeutics develops oral enzyme replacement therapies for rare digestive diseases driven by malabsorption. It targets patients with cystic fibrosis and exocrine pancreatic insufficiency. Lead candidate ANG003 is a non-porcine recombinant enzyme engineered to survive the gut, replacing legacy porcine extracts.","domain":"anagramtherapeutics.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":"unknown","githubStars":null,"industry":"biotech","investors":[],"lat":42.283639,"lng":-71.346996,"location":"Natick, MA","name":"Anagram Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":250000000,"currency":"USD","date":"2026-05-08","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-25","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"anagramtherapeutics-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-25","status":"attributed","url":null},{"fact":"existence","publisher":"anagramtherapeutics.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://anagramtherapeutics.com"},{"fact":"description","publisher":"anagramtherapeutics.com","retrievedAt":"2026-05-25","status":"self-reported","url":"https://anagramtherapeutics.com"}],"stage":"series-b+","techStack":["unknown"],"totalRaisedUsd":250000000,"updatedAt":"2026-05-25"}